Results
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 Dec 2024
Post
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma. The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation. EORTC and Immunocore today announce the randomisation of the first patient in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), investigating [...]
EORTC Melanoma Group Spring Meeting 2025
7 Nov 2024
Event
The EORTC Melanoma Group meeting will be held as a face-2-face event on 20 & 21 March 2025 in Frankfurt, Germany. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC Melanoma Group, and you have not received the registration link, please [...]
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
17 Sep 2024
Post
Important new results and an update on an EORTC trial in progress were reported at the ESMO Congress 2024, held in Barcelona from 13-17 September, further underlining the extent of EORTC’s commitment to innovative, independent cancer research. Prostate cancer Professor Silke Gillessen presented the primary results from EORTC GUCG-1333 (PEACE III)1, an international, randomised [...]
EORTC Melanoma Group Autumn Meeting 2024
6 May 2024
Event
The EORTC Melanoma Group autumn meeting will be held on 11-12 September 2024 in Barcelona, Spain and is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC [...]
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Post
The European Organisation for Research and Treatment of Cancer (EORTC) is pleased to announce a collaboration with Immunocore, which marks the beginning of the ground-breaking clinical trial ATOM investigating the adjuvant treatment of uveal melanoma with tebentafusp. This partnership marks a crucial step forward in our mission to enhance the prognosis and treatment options [...]
EORTC Melanoma Group Spring Meeting
25 Oct 2023
Event
The EORTC Melanoma Group Spring meeting will be held in Turin, Italy on 21-22 March 2024. It is only open to individual or site staff members of the group. Registrations for the meeting are open and the link was sent by email. In case you are an individual or site staff member of the EORTC [...]
